Clinical trial
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic…
NCT00255606 · Tampere University, Other · Completed
Key facts
| NCT number | NCT00255606 |
|---|---|
| Title | Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer |
| Official title | A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial |
| Lead sponsor | Tampere University, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, prednisone |
| Enrollment | 360 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Nov 21, 2005 |
| Last update posted | Jun 26, 2013 |
| Countries | Finland, Ireland, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: